Compare HITI & CRBU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HITI | CRBU |
|---|---|---|
| Founded | 2009 | 2011 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | Medicinal Chemicals and Botanical Products |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 213.6M | 179.7M |
| IPO Year | 2021 | 2021 |
| Metric | HITI | CRBU |
|---|---|---|
| Price | $2.48 | $2.29 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 4 |
| Target Price | $6.13 | ★ $10.75 |
| AVG Volume (30 Days) | 371.2K | ★ 1.2M |
| Earning Date | 03-17-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 3.64 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $23.73 | $1.63 |
| Revenue Next Year | $12.80 | $10.93 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.10 | $0.73 |
| 52 Week High | $4.06 | $3.53 |
| Indicator | HITI | CRBU |
|---|---|---|
| Relative Strength Index (RSI) | 59.64 | 66.85 |
| Support Level | $2.43 | $1.70 |
| Resistance Level | $2.51 | $2.66 |
| Average True Range (ATR) | 0.08 | 0.12 |
| MACD | 0.03 | 0.03 |
| Stochastic Oscillator | 91.06 | 93.45 |
High Tide Inc is a downstream-focused retailer of cannabis products, distributor, and seller of smoking accessories and cannabis lifestyle products. It is a vertically integrated company in the Canadian cannabis market with various brands in its portfolio such as Canna Cabana, Fastendr, Queen of Bud, Grasscity, Daily High Club, and others. The company's reportable operating segments are: Bricks and mortar, which generates maximum revenue, and E-commerce. Geographically, it derives maximum revenue from its business in Canada, followed by the United States of America, and other international markets.
Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) genome-editing biopharmaceutical company dedicated to developing transformative therapies for patients with devastating diseases. The company is focused on advancing two clinical-stage allogeneic CAR-T cell therapy product candidates for the treatment of patients with hematologic malignancies: Vispacabtagene regedleucel and CB-011. It operates in one reportable segment, which is the business of developing allogeneic CAR-T cell therapies. Geographically, it operates in the United States and the rest of the World, of which the United States derives the maximum revenue.